Revision Fusion: Why These Patients Keep Coming Back for Pain Meds

A recent retrospective cohort study takes a deep dive into how different are revision lumbar revision patients are in terms of postoperative pain and medication use — and the results may not surprise anyone who has spent time in a revision clinic.

The short version: revision fusion patients behave a lot like primary fusion patients in the early postoperative period. But over time, the curves begin to diverge dramatically.

And not in a good way.

Same Start, Different Finish

The investigators reviewed 1,938 patients who underwent elective 1–3 level lumbar fusion between 2018 and 2023. Of these, 1,498 were primary fusions and 440 were revisions. Using state prescription drug monitoring program (PDMP) data, they tracked opioid and non-opioid prescriptions at four key checkpoints: 30 days, 90 days, 1 year, and 2 years.

Here’s where things get interesting.

In the immediate postoperative window — up to 30 days — both groups looked remarkably similar in terms of opioid use. So, if you’re judging success purely by the first follow-up visit, revision patients don’t necessarily wave a red flag.

But by 90 days, the separation begins.

Revision patients consumed nearly double the opioid burden compared with primary fusion patients (428 vs. 219 morphine milligram equivalents). By one year, the gap widened substantially (1,142 vs. 382 MME), and by two years the difference was striking (1,550 vs. 497 MME).

In other words, revision patients aren’t just using more opioids — they’re staying on them much longer.

The Gabapentinoid Clue

Opioids weren’t the only medications telling a story.

Gabapentinoid use also began creeping up in revision patients around the 90-day mark, with 19.3% of revision patients using these agents compared with 13.4% of primary fusion patients.

That trend hints at something spine surgeons frequently suspect: the pain phenotype in revision patients may be more neuropathic and complex than the classic mechanical back pain seen in many primary fusion cases.

After all, by the time a patient reaches revision surgery, the lumbar ecosystem has usually been through a lot — scar tissue, nerve irritation, altered biomechanics, and sometimes adjacent segment degeneration.

The Real Culprit: Preoperative Opioids

When the authors ran multivariable analyses to determine what truly predicts long-term opioid use, one factor towered above the rest: preoperative opioid exposure.

Patients entering surgery with higher baseline opioid burdens were far more likely to continue using them long term.

Still, revision status itself remained an independent predictor of increased opioid use at 1 and 2 years—even after adjusting for other factors.

So, revision surgery appears to add its own layer of risk.

What This Means in the Clinic

For spine surgeons, the message is less about postoperative prescribing habits and more about preoperative strategy.

Revision patients may benefit from:

• More aggressive preoperative opioid weaning
• Clear counseling about the likelihood of persistent medication needs
• Early involvement of multidisciplinary pain management teams
• Closer surveillance for neuropathic pain patterns

Because the reality is this: revision surgery may fix the mechanical problem, but it doesn’t always reset the nervous system.

The Takeaway

Primary and revision fusion patients may look similar at the first postoperative visit, but their long-term medication trajectories tell a very different story.

Revision patients bring more than scar tissue into the operating room — they often carry a preexisting pain biology that persists long after the incision heals.

And for spine surgeons, understanding that trajectory might be just as important as getting the screws in the right place.

Origin Study Title: Revision Lumbar Fusion Patients Exhibit Higher Long-Term Opioid and Gabapentinoid Needs Despite Similar Early Postoperative Use

Authors: Olson, Jarod B.S.; Green, William A. B.S., MEd; Dalton, Jonathan M.D.; Ng, Mitchell M.D.; Baidya, Joydeep B.S.; Huang, Rachel B.S.; Oris, Robert J. B.S.; Herczeg, Chloe B.S.; Sherman, Matthew B.S.; Eichbaum, Yasmine B.S.; Baek, Gregorio B.S.; Mathew, Joshua B.S.; Lee, Yulia B.A.; Hitchner, Morgan B.S.; Duggan, Samuel B.S.; DeMario, Nick B.S.; Goldberg, Marco B.S.; Kaffenes, Anastasia B.S.; Cha, Thomas M.D.; Hilibrand, Alan S. M.D.; Vaccaro, Alexander R. M.D., Ph.D., M.B.A.; Kepler, Christopher K. M.D., M.B.A.; Schroeder, Gregory D. M.D.